Common questions about Kadcyla (FAQ)
Q: How is Kadcyla different from Herceptin (trastuzumab)?
A: Kadcyla is classified as an antibody-drug conjugate (ADC), which means it links the anti-HER2 antibody trastuzumab to a chemotherapy agent (DM1). Trastuzumab (Herceptin) is the antibody alone. Regulatory documents specify that the two products are not interchangeable and are not to be substituted for one another.
Q: What should I know about the potential side effects of Kadcyla?
A: Official safety information highlights several Important Safety Risks, including potential for liver injury (hepatotoxicity), heart problems, lung issues (pulmonary toxicity), and serious bleeding. Beyond these major warnings, the most common side effects reported in studies (ge 25% of patients) include fatigue, nausea, musculoskeletal pain, low platelet count, and headache.
Q: Are there specific vitamins or supplements that are known to interact with Kadcyla?
A: Regulatory-sourced patient information indicates that a patient's entire healthcare team must be informed of all medicines and products used, including supplements and over-the-counter drugs, as this information is relevant due to the potential for interactions or additive toxicities, particularly the risk of bleeding or liver issues.
Q: Can Kadcyla be used alone or always combined with other drugs?
A: According to official product information, Kadcyla is indicated as a single agent (used alone) for the treatment of HER2-positive breast cancer in the specific settings for which it is approved.
Q: What happens if I forget to mention an over-the-counter medicine to my healthcare team?
A: Official patient guidance emphasizes that patients are informed of the need to tell all healthcare providers (doctors, dentists, pharmacists) they are receiving Kadcyla. This disclosure is necessary because many common over-the-counter products can increase the risk of bleeding or liver issues when combined with Kadcyla.
Q: What kind of research exists about long-term effects after stopping Kadcyla?
A: Clinical trials, such as the KATHERINE study, have included long-term follow-up to observe patterns after patients stopped treatment. Researchers have reported measurements of Overall Survival (OS)—how long patients lived—over several years of observation when comparing Kadcyla to other treatments.
Q: Is it normal to feel a tingling sensation in my hands or feet while on this medicine?
A: Nerve damage, known as peripheral neuropathy, is a potential adverse reaction of the medicine. Official safety sources specifically list symptoms that may include numbness and tingling (paresthesia). Severe cases may require temporary treatment interruption or a dose reduction.
Q: Can Kadcyla cause hair loss like traditional chemo?
A: Hair loss, or alopecia, is not listed among the most frequently observed side effects (those affecting 25% or more of patients) detailed in the official regulatory safety information for Kadcyla.
Q: Can men use Kadcyla for breast cancer?
A: The medicine is indicated for the treatment of HER2-positive breast cancer in eligible patients. Regulatory-sourced patient guides state that the drug information and eligibility criteria are applicable to both men and women who meet the requirements for treatment.
Q: What are some common misunderstandings about how Kadcyla works?
A: Regulatory educational materials alert healthcare professionals to the potential risk of confusion between the different products Kadcyla (trastuzumab emtansine) and trastuzumab (Herceptin) due to the similarity in names and shared antibody component. It is noted that these products are not interchangeable and have different safety profiles.
Q: Does Kadcyla affect my ability to drive or operate machinery?
A: Official information states that it is not known whether Kadcyla affects the ability to drive or use machines. Official information indicates that patients who experience side effects such as infusion-related reactions, dizziness, or fatigue may have their ability to drive or operate machinery affected.
Q: What are the research themes around using Kadcyla in earlier stages of breast cancer?
A: Research conducted on Kadcyla for early breast cancer, such as the KATHERINE study, focused on key endpoints. Primary research themes focused on measuring Invasive Disease-Free Survival (iDFS)—the time patients were observed to be free from cancer recurrence or death—and Overall Survival (OS).
Q: Can people with kidney problems use Kadcyla?
A: According to official analysis, dose adjustments are not needed for patients who have mild or moderate kidney impairment. However, no dose recommendation can be made for patients with severe kidney impairment because data from studies in this population is limited.
Q: What precautions should be taken when handling Kadcyla at home, if any?
A: Kadcyla is prepared and administered exclusively by healthcare professionals in a hospital or clinic setting. Official regulatory documents define strict requirements for the storage of the unused vials and the disposal of the product at an approved waste disposal plant.
Q: What information is available about Kadcyla and lung inflammation or lung issues?
A: Official safety warnings note the risk of Pulmonary Toxicity, which includes Interstitial Lung Disease (ILD) and pneumonitis. Signs to watch for may include trouble breathing, cough, tiredness, and fluid in the lungs. Regulatory documents describe that permanent discontinuation of treatment is required upon the diagnosis of ILD or pneumonitis.
Q: Are older adults (seniors) treated differently with Kadcyla than younger people?
A: Official regulatory information states that there is insufficient data to establish separate evidence patterns for patients who are over 75 years of age. Dose adjustments based solely on age are not universally defined in the product information.
Q: Why are people often confused about the difference between Kadcyla and ado-trastuzumab emtansine?
A: Kadcyla is the trade name (brand name) for the medicine, and ado-trastuzumab emtansine (or T-DM1) is the official generic or chemical name for the single active ingredient. Both names refer to the exact same pharmaceutical product.
Q: Does Kadcyla cause fatigue, and if so, how severe is it usually?
A: Fatigue is listed as a very common adverse reaction, occurring in 25% or more of patients reported in clinical studies. Regulatory documents mention that fatigue has been reported at Grade ge 3 (a clinical measure of severity), which may require management or dose interruption.
Q: Are there any known issues with getting dental work while taking Kadcyla?
A: Official patient guidance indicates that due to the potential for a low platelet count (thrombocytopenia) and bleeding risk, patients are encouraged to have a dental check-up before starting treatment. It is noted that non-essential dental work may be avoided during treatment if possible.
Q: How quickly does Kadcyla leave the body after the last dose?
A: The rate at which the drug leaves the body is described by its half-life (the time it takes for half of the drug to be eliminated). The half-life of the trastuzumab component of Kadcyla is reported in regulatory documents to be about 7 days.
